EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variant

EpiVax Progresses on a Vaccine to Address SARS-CoV-2 Variants

/PRNewswire/ -- Today EpiVax, Inc. ("EpiVax") confirmed that the company's EPV-CoV-19 vaccine epitopes are 98.2% conserved in the new Omicron SARS-CoV-2...

Related Keywords

Nicole Ruggiero , Katie Porter , Epivax Therapeutics Inc , Epivax Inc , Business Development , Today Epivax , Epivax Therapeutics ,